Beth Seidenberg and Sean Harper (Westlake Village)
Corrected: Westlake targets $450M for Seidenberg's next life sciences fund
Life sciences VC firm Westlake Village BioPartners is ready to restock its capital reserves shortly after its success with bringing portfolio company Acelyrin to one …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.